These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24752068)

  • 1. Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model.
    Borriello L; Montès M; Lepelletier Y; Leforban B; Liu WQ; Demange L; Delhomme B; Pavoni S; Jarray R; Boucher JL; Dufour S; Hermine O; Garbay C; Hadj-Slimane R; Raynaud F
    Cancer Lett; 2014 Jul; 349(2):120-7. PubMed ID: 24752068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptor.
    Liu WQ; Megale V; Borriello L; Leforban B; Montès M; Goldwaser E; Gresh N; Piquemal JP; Hadj-Slimane R; Hermine O; Garbay C; Raynaud F; Lepelletier Y; Demange L
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4254-9. PubMed ID: 25091928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo.
    Chen Z; Ruan Q; Han S; Xi L; Jiang W; Jiang H; Ostrov DA; Cai J
    Breast Cancer Res Treat; 2014 May; 145(1):45-59. PubMed ID: 24710637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
    Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
    Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.
    Benatar T; Yang W; Amemiya Y; Evdokimova V; Kahn H; Holloway C; Seth A
    Breast Cancer Res Treat; 2012 Jun; 133(2):563-73. PubMed ID: 21997538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
    Yadav B; Taurin S; Larsen L; Rosengren RJ
    Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting VEGF-neuropilin interactions: a promising antitumor strategy.
    Peng K; Bai Y; Zhu Q; Hu B; Xu Y
    Drug Discov Today; 2019 Feb; 24(2):656-664. PubMed ID: 30315890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
    J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening.
    Starzec A; Miteva MA; Ladam P; Villoutreix BO; Perret GY
    Bioorg Med Chem; 2014 Aug; 22(15):4042-8. PubMed ID: 24961874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model.
    Gondi CS; Gorantla B; Bhujanga Rao AK; Amala K; Naidu MU; Jogi KV; Venkat Ramana G; Myneni PC; Junnarkar A; Rao JS
    Int J Oncol; 2011 Sep; 39(3):641-8. PubMed ID: 21674127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.
    Edwards SL; Poongavanam V; Kanwar JR; Roy K; Hillman KM; Prasad N; Leth-Larsen R; Petersen M; Marušič M; Plavec J; Wengel J; Veedu RN
    Chem Commun (Camb); 2015 Jun; 51(46):9499-502. PubMed ID: 25968110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
    Bae SM; Kim JH; Chung SW; Byun Y; Kim SY; Lee BH; Kim IS; Park RW
    Biomaterials; 2013 Mar; 34(8):2077-86. PubMed ID: 23245333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.